Saturday, May 7, 2022 8:00 AM – 10:00 AM ET Room B113–116
Mechanisms of Resistance to Therapy
- Jim Song, Texas A&M Univ.
- William Lu, Univ. of Arkansas for Med. Sci.
- Arshmeet K. Chawla, Univ. of Connecticut Hlth. Ctr., β-adrenergic signaling modulates the development and activity of erythroid suppressor cells
- Jianmei Wu Leavenworth, Univ. of Alabama at Birmingham, Remodeling of the tumor microenvironment via disrupting effector Treg activity augments response to checkpoint blockade
- Avery Janese Salmon, Univ. of Texas MD Anderson Cancer Cntr. UTHealth Grad. Sch. of Biomed. Sci., BHLHE40: Required for regulation of effector T cells and remodeling of tumor microenvironment during immune checkpoint therapy
- Adam L. Burrack, Univ. of Minnesota, TNF-α blockade improves immunotherapy efficacy by altering the tumor microenvironment and enhancing tumor-specific T cell function in pancreatic ductal adenocarcinoma
- Nathan E. Reticker-Flynn, Stanford Univ. Sch. of Med., Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immune tolerance
- Evelyn M. Nguyen, Mem. Sloan Kettering Cancer Ctr., Targeting LSD1 rescues MHC class I antigen presentation and promotes immune checkpoint blockade response in small cell lung cancer
- Vishnu Modur, Cincinnati Children’s Hosp. Med. Ctr., Tumors bearing defective transcription elongation are immune hot but resistant to immune checkpoint inhibitors